Zusammenfassung
Bei Patienten mit fortgeschrittener Herzinsuffizienz findet das Prinzip der medikamentösen Entlastung mit Vasodilatatoren als „dritte Säule“ neben Digitalis und Diuretika zunehmend Anwendung [6, 7, 10, 18, 30, 32, 38, 55]. Hierzu kommen entweder überwiegend arteriell angreifende, d. h. die Nachlast senkende Vasodilatatoren (z. B. Minoxidil, Hydralazin, Nifedipin, Phentolamin) oder Nitrate, die über eine Venodilatation die Vorlast reduzieren, in Betracht. Eine Mittelstellung nehmen Substanzen wie Natriumnitroprussid und Captopril ein, die sowohl im arteriellen als auch im venösen Bereich dilatierend wirken.
This is a preview of subscription content, log in via an institution.
Preview
Unable to display preview. Download preview PDF.
Literatur
Arnold SB, Williams RL, Ports TA, Baughman RA, Benet LZ, Parmley WW, Chatterjee K (1979) Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Int Med 91: 345–349
Awan NA, Lee G, DeMaria AN, Mason DT (1981) Ambulatory prazosin treatment of chronic congestive heart failure: Development of late tolerance reversible by higher dosage and interrupted substituation therapy. Am Heart J 101: 541–547
Bailar JC, Louis TA, Lavori PW, Polansky M (1984) Studies without internal controls. N Engl J Med 311: 156–162
Barankay A, Göb E, Richter JA (1981) Treatment of hypertension in coronary bypass surgery. Clinical experience with urapidil. Arzneimittelforsch 31: 849–852
Beiz GG (1984) Die Wirkungen von Urapidil auf das kardiovaskuläre System des Menschen. Symposium: Urapidil bei Hypertonie und Herzinsuffizienz. IX. Europäischer Kongress für Kardiologie, 11. Juli, Düsseldorf
Bertel O (1983) Behandlung der Herzinsuffizienz mit Vasodilatatoren. Fortschr Med 101: 1437–1439
Braunwald E (1984) Vasodilator therapy of heart failure. New Engl J Med 310: 459–461
Bruckschen EG, Henze F, Michael G (1978) Clinical trials of urapidil. Review of human pharmacological studies with a summary of a multicenter study. Arzneimittelforsch 28: 1176–1184
Bruckschen EG, Haerlin R (1980) Hochdrucktherapie mit Ebrantil. Therapiewoche 30: 7850–7851
Cohn JN, Franciosa JA (1977) Vasodilator therapy of cardiac failure. New Engl J Med 297: 228–258
Collins P, Sheridan D (1985) Improvement in angina pectoris with alpha adrenoceptor blockade. Br Heart J 53: 488–492
Desch CE, Magorien RD, Triffon DW, Blanford MF, Unverferth DV, Leier CV (1979) Development of pharmacodynamic tolerance to prazosin in congestive heart failure. Am J Cardiol 44: 1178–1182
Elkayam U, Lejemtel TH, Mathur M, Ribner HS, Frishman WH, Strom J, Sonnenblick EH (1979) Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol 44: 540–545
Eltze M (1979) Investigation on the mode of action of a new antihypertensive drug, urapidil, in the isolated rat vas deferens. Eur J Pharmacol 59: 1–9
Franciosa JA (1984) Exercise testing in chronic congestive heart failure. Am J Cardiol 53: 1447–1450
Franciosa JA, Dunkman B, Leddy CL (1984) Hemodynamic effects of vasodilators and longterm response in heart failure. JACC 6: 1521–1530
Franke N, Schmucker P, van Ackern K, Reichert B (1980) Antihypertensive Therapie mit Urapidil während der Narkose. Therapiewoche 30: 880–886
Freis ED (1984) Preload and afterload reduction in treating congestive heart failure. J Cardiovasc Pharmac 6: 895–902
Furberg CD, Yusuf S, Thom TJ (1984) Potential for altering the natural history of congestive heart failure: Need for large clinical trials. Am J Cardiol 55: 45A-47A
Gless K-H, Gram N, Helmstädter V (1978) Die Wirkung von intravenös appliziertem Urapidil auf den Blutdruck bei Patienten mit krisenhaft erhöhtem Blutdruck. Therapiewoche 28: 6266–6270
Graham RM (1984) Selective alphai-adrenergic antagonists: Therapeutically relevant antihypertensive agents. Am J Cardiol 53: 16A-20A
Harper RW, Claxton H, Anderson S, Pitt A (1980) The acute and chronic haemodynamic effects of prazosin in severe congestive heart failure. Med J Aust 2 (Suppl): 36–38
Higginbotham M, Morris K, Coleman RE, Cobb FR (1982) Is long-term ambulatory therapy with prazosin effective in chronic heart failure? Circulation 66 (Suppl II): 11–210
Kern MJ, Horowitz JD, Ganz P, Gaspar J, Colucci WS, Lorell BH, Barry WH, Mudge GH (1985) Attenuation of coronary vascular resistance by selective alpha1-adrenergic blockade in patients with coronary artery disease. J Am Coll Cardiol 5: 840–846
Kobrin I, Gallo A, Pergram BL, Frohlich ED (1984) Urapidil in normotensive and spontaneously hypertensive rats: The effects on systemic and regional hemodynamics and cardiac mass. J Hypertens 2: 317–320
Kobrin I, Gallo A, Kumar A, Pegram BL, Frohlich ED (1984) Immediate hemodynamic changes produced by urapidil in normotensive and spontaneously hypertensive rats. Clin Exp Hypertens A6: 685–697
Kobrin I, Amodeo C, Ventura HO, meserli FH, Fröhlich ED (1985) immediate hemodynamic effects of urapidil in patients with essential hypertension. Am J Cardiol 55: 722–725
Kuhn H, Boch H, Lösse B (1981) Wirkung einer chronischen Verabreichung von Prazosin bei Patienten mit kongestiver Kardiomyopathie. Z Kardiol 70: 501–507
Langer SZ (1981) Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32: 337–362
Levine TB (1985) Role of Vasodilators in the Treatment of Congestive Heart Failure. Am J Cardiol 55: 32A-35A
Markham RV, Corbett JR, Gilmore A, Pettinger WA, Firth BG (1983) Efficacy of prazosin in the management of chronic congestive heart failure: A 6-month randomized, double-blind, placebo-controlled study. Am J Cardiol 51: 1346–1352
Mason DT (1978) Ventricular afterload reduction in management of congestive heart failure - A rational new concept that has rapidly come of age by vasodilator drugs. Clin Cardiol 1: 55–59
McFate-Smith W (1985) Epidemiology of congestive heart failure. Am J Cardiol 55: 3A-8A
McMahon FG (1978) Management of essential hypertension. Futura, Mount Kisco NY
Nicholis DP, Harron DWG, Shanks RG (1981) Acute and chronic cardiovascular effects of indo- ramin and prazosin in normal man. Br J Clin Pharmacol 6: 61S-66S
Packer M, Meller J, Gorlin R, Herman MV (1979) Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation 59: 531–539
Packer M, Meller J, Medina N, Yushak M, Gorlin R (1982) Serial hemodynamic studies indicate that early tolerance to prazosin in heart failure is not reversible (abstr). Circulation 66 (Suppl II): 11–210
Packer M (1983) Vasodilator and inotropic therapy for severe chronic heart failure: Passion and scepticism. JACC 2: 841–852
Rasmussen K (1982) Hemodynamic effects of alpha receptor blockade during acute administration and chronic treatment. Acta Med Scand (Suppl) 665: 83–85
Reiterer W (1981) Der Akuteffekt von Urapidil (i.v.) auf die Belastungshämodynamik bei Hypertonikern mit Linksherzinsuffizienz. In: Kaufmann W, Bruckschen EG (Hrsg) 1. Urapidil- Symposium, 20.-21.11.1981. Excerpta Medica, Amsterdam Oxford Princeton, S 166–178
Robertson RM, Bernard YD, Carr RK, Robertson D (1983) Alpha-adrenergic blockade in vasotonic angina: Lack of efficacy of specific alpha-1 receptor blockade with prazosin. J Am Coll Cardiol 2: 1146–1150
Rouleau J-L, Warnica JW, Burgess JH (1981) Prazosin and congestive heart failure: Short- and long-term therapy. Am J Med 71: 147–152
Schoetensack W, Bischler P, Dittmann EC, Steinijans V (1977) Studies on the influence of the antihypertensive drug urapidil on blood circulation and its regulation in animal experiments. Arzneimittelforsch 27: 1908–1919
Schoetensack W, Bruckschen EG, Zech K (1983) Urapidil. In: Scriabine A (ed) New drugs annual: Cardiovascular drugs. Raven, New York, pp 19–48
Schuster P (1981) Einsatz des Antihypertonikums Ebrantil bei Hochdruckkrisen. Klinikarzt 10: 202–211
Silber S, Schwaiger M, Klein U, Rudolph W (1980) Quantitative Beurteilung der linksventrikulären Funktion mit der Radionuklid-Ventrikulographie. Herz 5: 146–158
Silber S, Krause H, Garner C, Theisen K, Jahrmärker H (1983) Anti-Ischemic effects of an 80-mg tablet of isosorbide dinitrate in sustained-release form before and after 2 weeks treatment with 80mg once daily or twice daily. Z Kardiol 72 (Suppl 3): 211–217
van Zwieten PA (1984) Mechanism of antihypertensive action of urapidil in animals. Urapidil workshop, Gottlieben, 5th-6th July
Weber KT, Kinasewitz GT, West JS, Janicki JS, Reichek N, Fishman AP (1980) Long-term vasodilator therapy with trimazosin in chronic cardiac failure. N Eng J Med 303: 242–250
Wießmann K-J, Münninghoff J, Krüger C (1983) Antihypertensive Therapie mit Urapidil bei Patienten mit obstruktiven Lungenerkrankungen. Fortschr Med 101: 291–294
Wilson JR, Martin JL, Schwartz D, Ferraro N (1984) Exercise intolerance in patients with chronic heart failure: Role of impaired nutritive flow to skeletal muscle. Circulation 69: 1079–1087
Winniford MD, Filipchuk N, Hillis LD (1983) Alpha-adrenergic blockade for variant anginga: A long term, double-blind, randomized trial. Circulation 67: 1185–1188
Zähringer J, Klepzig M, Greif J, Ludwig B, Strauer B (1984) Therapie der hypertensiven Krise mit Urapidil. Fortschr Med 102: 624–628
Zech K, Sturm E, Steinijans V (1981) Pharmakokinetik und Metabolismus von Urapidil bei Tier und Mensch. In: Kaufmann W, Bruckschen EG (Hrsg) 1. Urapidil-Symposium, 20–21.11.1981, Bad Kreuznach. Excerpta Medica, Amsterdam Oxford Princeton, S 50–64
Zelis R, Flaim SF, Moskowitz RM, Nellis SH (1979) How much can we expect from vasodilator therapy in congestive heart failure? Circulation 59: 1092–1097
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Silber, S., Hany, F., Weber, M., Theisen, K., Jahrmärker, H. (1986). Wirkung des selektiven Alpha1-Blockers Urapidil auf die Hämodynamik von Patienten mit chronischer Herzinsuffizienz ohne arterielle Hypertonie. In: Bussmann, WD., Just, H. (eds) Vasoaktive Substanzen bei Herzinsuffizienz. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71486-3_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-71486-3_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-16946-8
Online ISBN: 978-3-642-71486-3
eBook Packages: Springer Book Archive